During the development of antibody therapeutics, regulators now require assays to evaluate Fc effector function demonstrating immune cell-mediated killing via ADCC and ADCP rather than a surrogate endpoint for antibody engagement of antigen on target cells. Eurofins DiscoverX’s KILR® cytotoxicity assay platform specifically measures antibody-mediated killing of antigen-expressing target cells in co-culture with effector cells. This platform is now available as ready-to-use bioassays for several tumor models, including Raji and Daudi, for use in screening and lot-release applications. These bioassays are qualified with Rituximab and demonstrate high repeatability and inter-analyst performance.
Register Now
|
Event capacity:
|
N/A
|
Event location:
|
|
Event date:
|
6/16/2022, 8:00 AM - 8:00 PM
|
|